Biotechnology

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug inChina. - XPOVIO® as a monotherapy in patients with relap...

2025-07-28 18:49 2486

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for canc...

2025-07-28 10:40 1914

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive prof...

2025-07-28 08:11 2143

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials inSingapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therap...

2025-07-28 07:33 1783

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has design...

2025-07-25 22:59 3789

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and...

2025-07-25 10:30 2981

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887". The clinical-stage biotech company priced its I...

2025-07-25 09:00 3157

Angel Yeast Showcases Innovative Yeast Protein at 2025 IFT FIRST in Chicago

CHICAGO, July 24, 2025 /PRNewswire/ -- The 2025 IFT FIRST (Food Improved by Research, Science, and Technology), one of the world's largest food science and innovation expos, recently took place fromJuly 13 to 16 in Chicago. At the expo, Angel Yeast (SHA:600298) showcase...

2025-07-24 21:00 2466

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical de...

2025-07-24 19:30 2245

Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment

CHICAGO, July 24, 2025 /PRNewswire/ -- Fapon, a global leader in life sciences, will unveil its innovative one-stop IVD solutions at ADLM 2025, fromJuly 29 to 31 in Chicago, IL. Fapon aims to be the trusted global partner for laboratories and IVD manufacturers with advanced innovations and dedica...

2025-07-24 19:00 1711

Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378

CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB37...

2025-07-23 21:31 2697

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 * HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma ...

2025-07-23 20:36 2173

Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025

SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will take place inShanghai, China, from September 9–12, 2025, co-hosted by Chinese Stomatological Association and Reed Sinopharm Exhibitions. Organized an...

2025-07-23 17:53 2187

Singapore-Based Innovative Biomedical Start-Up Achieves 'Strategic Triumph' to Conquer Chinese Med-Tech Market

* NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people * Syntellix' product approval for China is the largest and most important success in the company's history; product approval inChina was the company's most important strat...

2025-07-23 15:35 2947

Samsung Biologics reports second quarter 2025 financial results

* Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion * Recorded Q2'25 consolidated operating profit of KRW 475.6 billion * Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940...

2025-07-23 14:54 2032

BostonGene Receives Frost & Sullivan's 2025 North American Enabling Technology Leadership Award for Redefining Precision Oncology with AI and Multiomics Innovation

BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 /PRNewswire/ -- Frost & Sullivan has named  BostonGene the recipient of the 2025...

2025-07-22 22:00 2102

METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting...

2025-07-22 15:52 2337

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced thatthe U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of ad...

2025-07-22 10:25 2224

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving inAsia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp o...

2025-07-22 10:07 2811

CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area

SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry.  Building on this success, CPHI & PMEC Shenzhen 2025  will tak...

2025-07-21 14:31 2158
1 ... 27282930313233 ... 341

Week's Top Stories